Gut bacterial bile salt hydrolase activity correlates with cardiovascular risk: a case-control study

Authors

DOI:

https://doi.org/10.22141/2308-2097.54.4.2020.216711

Keywords:

bile salt hydrolase activity, dyslipidemia, cardiovascular risk

Abstract

Background. Serum cholesterol may be regulated by bile acid metabolism in the gut that depends on bacterial bile salt hydrolase (BSH) activity. There are limiting data regarding the clear effect of BSH on host lipid metabolism and cardiovascular risk (CVR). The investigation aimed to assess the relationship between the gut bacterial BSH relative activity (RA) and serum cholesterol with CVR levels. Materials and methods. The investigation was conducted as a case-control study and included 26 almost healthy participants (a control group) and 77 patients with dyslipidemia and without anamnesis of major cardiovascular events (a case group). The total RA of gut BSH, lipid profile, and CVR level according to 5 risk scores were assessed. Results. The RA of BSH was higher in healthy adults comparing to participants with dyslipidemia (p < 0.001). There were found moderate negative correlation between RA of gut bacterial BSH and total cholesterol (TC) (–0.38) and moderate correlation with low-density lipoproteins (LDL) (–0.36) with linear relationship that is defined by equation: LDL = –5.33 • RA of BSH + 4.479. It was revealed that with increasing of RA of gut bacterial BSH, the risk of dyslipidemia decreased (р < 0.001), OR = 1.06 • 10–10 (95% confidence interval; 2.5 • 10–15 – 4.5 • 10–6). There was found a moderate negative correlation between RA of gut bacterial BSH and CVR levels according to Globorisk score (–0.34), Fra­mingham score (–0.34), 2013 ACC/AHA algorithm (–0.32), PROCAM score (–0.35), and WHO risk chart (–0.34). Conclusions. The total RA of the gut bacterial BSH negatively correlated with TC, LDL, and CVR levels according to 5 risk scores and was negatively associated with the risk of dyslipidemia.

References

Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. J Am Coll Cardiol. 2019 Nov 19;74(20):2529-2532. doi:10.1016/j.jacc.2019.10.009.

WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019 Oct;7(10):e1332-e1345. doi:10.1016/S2214-109X(19)30318-3.

Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. doi:10.1093/eurheartj/ehz455.

Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi:10.1093/eurheartj/ehx144.

Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020 Apr;21(4):225-245. doi:10.1038/s41580-019-0190-7.

Charach G, Argov O, Geiger K, Charach L, Rogowski O, Grosskopf I. Diminished bile acids excretion is a risk factor for coronary artery disease: 20-year follow up and long-term outcome. Therap Adv Gastroenterol. 2017 Dec 4;11:1756283X17743420. doi:10.1177/1756283X17743420.

Chiang JY. Bile acids: regulation of synthesis. J Lipid Res. 2009 Oct;50(10):1955-66. doi:10.1194/jlr.R900010-JLR200.

Reis SA, Conceição LL, Rosa DD, Siqueira NP, Peluzio MCG. Mechanisms responsible for the hypocholesterolaemic effect of regular consumption of probiotics. Nutr Res Rev. 2017 Jun;30(1):36-49. doi:10.1017/S0954422416000226.

Urdaneta V, Casadesús J. Interactions between Bacteria and Bile Salts in the Gastrointestinal and Hepatobiliary Tracts. Front Med (Lausanne). 2017 Oct 3;4:163. doi:10.3389/fmed.2017.00163.

Lau K, Srivatsav V, Rizwan A, et al. Bridging the Gap between Gut Microbial Dysbiosis and Cardiovascular Diseases. Nutrients. 2017 Aug 10;9(8):859. doi:10.3390/nu9080859.

Geng W, Lin J. Bacterial bile salt hydrolase: an intestinal microbiome target for enhanced animal health. Anim Health Res Rev. 2016 Dec;17(2):148-158. doi:10.1017/S1466252316000153.

Song Z, Cai Y, Lao X, et al. Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome. Microbiome. 2019 Jan 23;7(1):9. doi:10.1186/s40168-019-0628-3.

Huijghebaert SM, Hofmann AF. Influence of the amino acid moiety on deconjugation of bile acid amidates by cholylglycine hydrolase or human fecal cultures. J Lipid Res. 1986 Jul;27(7):742-52.

Joyce SA, MacSharry J, Casey PG, et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci U S A. 2014 May 20;111(20):7421-6. doi:10.1073/pnas.1323599111.

Hajifathalian K, Ueda P, Lu Y, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015 May;3(5):339-55. doi:10.1016/S2213-8587(15)00081-9.

D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008 Feb 12;117(6):743-53. doi:10.1161/CIRCULATIONAHA.107.699579.

Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73. doi:10.1161/01.cir.0000437741.48606.98.

Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation. 2002 Jan 22;105(3):310-5. doi:10.1161/hc0302.102575.

Guo CF, Li JY. Hypocholesterolaemic action of Lactobacillus casei F0822 in rats fed a cholesterol-enriched diet. International Dairy Journal. 2013;32(2):144-149. doi:10.1016/j.idairyj.2013.04.001Get.

Li H, Xu G, Shang Q, et al. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 alpha-hydroxylase. Metabolism. 2004 Jul;53(7):927-32. doi:10.1016/j.metabol.2004.01.017.

Charach G, Grosskopf I, Rabinovich A, Shochat M, Weintraub M, Rabinovich P. The association of bile acid excretion and atherosclerotic coronary artery disease. Therap Adv Gastroenterol. 2011 Mar;4(2):95-101. doi:10.1177/1756283X10388682.

Downloads

Published

2020-09-01

Issue

Vol. 54 No. 4 (2020)

Section

Original Researches

License

Copyright (c) 2020 GASTROENTEROLOGY

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

  1. The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
  2. Directing  the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
  3. The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
  4. The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
  5. The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
  6. The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
  7. The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.